Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Discovery of a structural class of antibiotics with explainable deep learning

PROVIDER: PRJNA1026995 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26360400_1.fastq.gz	Fastqsanger.gz
	SRR26360400_2.fastq.gz	Fastqsanger.gz
	SRR26360401_1.fastq.gz	Fastqsanger.gz
	SRR26360401_2.fastq.gz	Fastqsanger.gz
	SRR26360402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Prioritization of enhancer mutations by combining allele-specific chromatin accessibility with motif analysis and deep learning

Project description:Genomic sequence variation within enhancers and promoters can have a significant impact on the cellular state and phenotype. However, sifting through the millions of candidate variants in a personal genome or cancer genome, to identify only those variants that impact enhancer function, remains a major challenge. Prioritization of non-coding genome variation benefits from explainable AI to predict and interpret the impact of a mutation on gene regulation. Here we apply a specialized deep learning model to 10 phased melanoma genomes and identify functional enhancer mutations with allelic imbalance of chromatin accessibility and gene expression.

2021-03-03 | GSE159965 | GEO

Project description:A deep learning approach to antibiotic discovery

| PRJNA598708 | ENA

Thermal proteome profiling of stationary-phase E. coli treated with semapimod

Project description:There is a need to discover and develop non-toxic antibiotics that are effective against metabolically dormant bacteria, which underlie chronic infections and promote antibiotic resistance. Traditional antibiotic discovery has historically favored compounds effective against actively metabolizing cells, a property that is not predictive of efficacy in metabolically inactive contexts. Here, we combine a stationary-phase screening method with deep learning-powered virtual screens and toxicity filtering to discover compounds with lethality against metabolically dormant bacteria and favorable toxicity profiles. The most potent and structurally novel compound without any obvious mechanistic liability was semapimod, an anti-inflammatory drug effective against stationary-phase E. coli and A. baumannii. Integrating microbiological assays, biochemical measurements, and single-cell microscopy, we show that semapimod selectively disrupts and permeabilizes the bacterial outer membrane by binding lipopolysaccharide. This work illustrates the value of harnessing non-traditional screening methods and deep learning models to identify non-toxic antibacterial compounds that are effective in infection-relevant contexts.

2023-08-21 | PXD044230 | Pride

Covalent penicillin-protein conjugates elicit anti-drug antibodies that are clonally and functionally restricted

Project description:Many archetypal and emerging classes of small-molecule therapeutics form covalent 38 protein adducts. In vivo, both the resulting conjugates and their off-target side conjugates have the potential to elicit antibodies, with implications for allergy and drug sequestration. Although β-lactam antibiotics are a drug class long associated with these immunological phenomena, the molecular underpinnings of off-target drug protein conjugation and consequent drug-specific immune responses remain incomplete. Here, using the classical β-lactam penicillin G (PenG) we have now probed the B and T cell determinants of drug-specific IgG responses to such conjugates in mice. Deep clonotyping reveals a dominant murine clonal antibody class encompassing phylogenetically-related IGHV1, IGHV5 and IGHV10 subgroup gene segments. Protein NMR and x-ray structural analyses reveal that these drive structurally convergent binding modes in adduct-specific antibody clones. Their common primary recognition mechanisms of the penicillin side-chain moiety (phenylacetamide in PenG)—regardless of CDRH3 length—limits cross-reactivity against other β-lactam antibiotics. This immunogenetics-guided discovery of the limited binding solutions available to antibodies against side products of an archetypal covalent inhibitor now suggests future potential strategies for the ‘germline-guided reverse engineering’ of such drugs away from unwanted immune responses.

2024-08-08 | PXD052026 | Pride

Solanum lycopersicum

Project description:Genome-wide cis-decoding for expression designing in tomato using cistrome data and explainable deep learning

| PRJDB12795 | ENA

A Deep Learning based Efficacy Prediction System for Drug Discovery

Project description:A Deep Learning based Efficacy Prediction System for Drug Discovery

| PRJNA693487 | ENA

De novo inference of thermodynamic binding energies using deep learning models of in vivo transcription factor binding

Project description:We introduce Affinity Distillation (AD), a method for extracting thermodynamic affinities de-novo from in-vivo immunoprecipitation experiments using deep learning. We show that neural networks modeling base-resolution in-vivo binding profiles of yeast and mammalian TFs can accurately predict energetic impacts of varying underlying DNA sequence on TF binding. Systematic comparisons between Affinity Distillation predictions and other predictive algorithms consistently show that Affinity Distillation more accurately predicts affinities across a wide range of TF structural classes and DNA sequences. Affinity Distillation relies on in-silico marginalization against many sequence backgrounds, resulting in a higher dynamic range and more accurate predictions than motif discovery algorithms. Moreover, we show that Affinity Distillation can learn differential paralog-specific affinities, thereby making it possible to more accurately reconstruct regulatory networks in cells.

2022-06-29 | GSE207001 | GEO

A Deep Learning based Efficacy Prediction System for Drug Discovery [Perillen]

Project description:A Deep Learning based Efficacy Prediction System for Drug Discovery [Perillen]

| PRJNA693496 | ENA

A Deep Learning based Efficacy Prediction System for Drug Discovery [Trametinib]

Project description:A Deep Learning based Efficacy Prediction System for Drug Discovery [Trametinib]

| PRJNA693497 | ENA

Wong2024 - Discovery of a structural class of antibiotics with explainable deep learning

Project description:The authors use a large dataset (>30k) to train an explainable graph-based model to identify potential antibiotics with low cytotoxicity. The model uses a substructure-based approach to explore the chemical space. Using this method, they were able to screen 283 compounds and identify a candidate active against methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci. Model Type: Predictive machine learning model. Model Relevance: The model predicts the probability of growth inhibition. Model Encoded by: Sarima Chiorlu (Ersilia) Metadata Submitted in BioModels by: Zainab Ashimiyu-Abdusalam Implementation of this model code by Ersilia is available here: https://github.com/ersilia-os/eos18ie

2024-05-08 | MODEL2405080002 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data